Latest Vimpat Stories
* New antiepileptic drug with a novel mechanism of action * Vimpat(R) helped people with epilepsy who still had uncontrolled partial onset seizures with current treatment * Vimpat(R) will be available in the U.S.
UCB has announced that the European Commission has approved Vimpat for the treatment of epilepsy in patients 16 years and older.
Press release: regulated information UCB announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending that the European Commission grants a marketing authorisation for lacosamide, proposed trade name Vimpat(TM), for the adjunctive treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy, aged 16 years and older.
- Small missiles, especially grape, canister, fragments of iron, and the like, when fired, as upon an enemy at close quarters.
- To fire mitraille at.